Clinical application of midtrimester non‐invasive fetal <i>RHD</i> genotyping and identification of <i>RHD</i> variants in a mixed‐ethnic population

Abstract

Non-invasive routine antenatal RHD genotyping at 24 weeks of pregnancy is a highly accurate method, resulting in the avoidance of 95% of unnecessary administrations of anti-D immunoglobulin, with no false negative results.